Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease
Open Access
Abstract
A major clinical feature in multiple myeloma is the development of osteolytic bone disease. The increase in bone destruction is due to uncontrolled osteoclastic bone resorption. Until recently the factors responsible for mediating the increase in osteoclast formation in myeloma have been unclear. However, recent studies have implicated a number of factors, including the ligand for receptor activator of NFκB (RANKL) and macrophage inflammatory protein-1α. The demonstration that increased osteoclastic activity plays a central role in this process and the identification of molecules that may play a critical role in the development of myeloma bone disease have resulted in studies aimed at identifying new approaches to treating this aspect of myeloma. Studies have been performed to determine the ability of recombinant osteoprotegerin (Fc.OPG), a soluble decoy receptor for RANKL, and potent new bisphosphonates to inhibit the development of myeloma bone disease in the 5T2MM murine model of multiple myeloma. Fc.OPG was shown to prevent the development of osteolytic bone lesions in 5T2MM bearing animals. These changes were associated with a preservation of the cancellous bone loss induced by myeloma cells and an inhibition of osteoclast formation. Bisphosphonates, including ibandronate and zoledronic acid, were also shown to inhibit the development of osteolytic bone lesions in the 5T2MM model and alternative models of myeloma bone disease. Bisphosphonates and Fc.OPG are effective inhibitors of the development of osteolytic bone lesions in pre-clinical murine models of myeloma bone disease. Cancer 2003;97(3 Suppl):818–24. © 2003 American Cancer Society. DOI 10.1002/cncr.11125Keywords
This publication has 38 references indexed in Scilit:
- Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myelomaBritish Journal of Haematology, 2001
- Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trialBritish Journal of Haematology, 1998
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myelomaBone, 1994
- The assessment of vertebral deformity: A method for use in population studies and clinical trialsOsteoporosis International, 1993
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorptionEuropean Journal of Haematology, 1992
- Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.Journal of Clinical Investigation, 1991
- Quantitative histology of myeloma‐induced bone changesBritish Journal of Haematology, 1982